What's in Ascentage Pharma Group Inc.'s pipeline?

Ascentage Pharma Group Inc. has 18 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 5 in Phase 2, 8 in Phase 1.

Which companies overlap with Ascentage Pharma Group Inc.'s portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Eisai Inc., Grupo Argentino de Tratamiento de la Leucemia Aguda, Janssen Korea, Ltd., Korea, Janssen Research & Development, LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ascentage-pharma-group-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Ascentage Pharma Group Inc. — Portfolio Competitive Intelligence Brief

Ascentage Pharma Group Inc. pipeline: 2 marketed, 0 filed, 3 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 5 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Rd	Rd	marketed	BCL-2 inhibitor	BCL-2	Oncology
Azacitidine Injection	Azacitidine Injection	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)	Oncology
APG-2575(Lisaftoclax )	APG-2575(Lisaftoclax )	phase 3	BCL-2/BCL-xL inhibitor	BCL-2, BCL-xL	Oncology
Lisaftoclax (APG-2575)	Lisaftoclax (APG-2575)	phase 3	BCL-2/BCL-xL inhibitor	BCL-2, BCL-xL	Oncology
lisaftoclax +BTK inhibitor	lisaftoclax +BTK inhibitor	phase 3	BCL-2 inhibitor + BTK inhibitor combination	BCL-2 and BTK (Bruton's tyrosine kinase)	Oncology

Therapeutic area mix

Oncology · 7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Eisai Inc. · 1 shared drug class
Grupo Argentino de Tratamiento de la Leucemia Aguda · 1 shared drug class
Janssen Korea, Ltd., Korea · 1 shared drug class
Janssen Research & Development, LLC · 1 shared drug class
Memorial Sloan Kettering Cancer Center · 1 shared drug class
NHS Greater Glasgow and Clyde · 1 shared drug class
Nanfang Hospital, Southern Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ascentage Pharma Group Inc.:

Cite this brief

Drug Landscape (2026). Ascentage Pharma Group Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ascentage-pharma-group-inc. Accessed 2026-05-16.